Public Employees Retirement Association of Colorado takes position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Public Employees Retirement Association of Colorado purchased a new stake in Cellebrite DI Ltd. in the second quarter. (NASDAQ:CLBT – Free Report), the company said in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,900 shares of the company, worth approximately $71,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in CLBT. Parallel Advisors LLC grew its holdings in shares of Cellebrite DI by 75.0% in the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after purchasing an additional 1,500 shares during the period. Central Asset Investments & Management Holdings HK Ltd acquired a new position in shares of Cellebrite DI in the 4th quarter valued at $113,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in Cellebrite DI by 7.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 7,086,158 shares of the company’s stock worth $56,446,000 after purchasing an additional 514,858 shares during the period. Quadrature Capital Ltd acquired a new position in Cellebrite DI in the 4th quarter worth $2,222,000. Finally, Crosslink Capital Inc. raised its stake in Cellebrite DI increased by 1.4% in the 4th quarter. Crosslink Capital Inc. now owns 3,240,480 shares of the company’s stock worth $28,063,000 after purchasing an additional 44,520 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s shares.

Wall Street analysts predict growth

A number of stock analysts have recently commented on the stock. TD Cowen raised their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Monday, September 23. Deutsche Bank Aktiengesellschaft raised their target price on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 16. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14. Bank of America raised their target price on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16. Finally, Craig Hallum raised his price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, September 25. Eight investment analysts have rated the stock with a buy rating. According to data from MarketBeat, the stock has a consensus rating of Buy and an average price target of $18.57.

Check out our latest analysis on CLBT

Cellebrite DI Stock Performance

CLBT stock opened at $16.85 on Monday. The company has a fifty-day moving average of $15.61 and a 200-day moving average of $12.86. The company has a market cap of $3.47 billion, a price-to-earnings ratio of -29.05, a PEG ratio of 2.32, and a beta of 1.52. Cellebrite DI Ltd. has a 52-week low of $6.36 and a 52-week high of $17.82.

Cellebrite DI (NASDAQ:CLBT – Get Free Report) last reported its quarterly results on Thursday, August 15. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The company had revenue of $95.70 million during the quarter, compared to the consensus estimate of $91.94 million. In the same quarter last year, the company earned $0.05 earnings per share. The company’s revenue for the quarter rose 24.8% year over year. As a group, sell-side analysts predict that Cellebrite DI Ltd. will record a profit per share of 0.31 for the current financial year.

About Cellebrite DI

(Free report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas and the Asia-Pacific. The company’s DI solutions suite enables users to collect, assess, analyze and manage digital data throughout the entire investigation cycle related to legally sanctioned investigations used in various cases, including child exploitation, homicide, counter-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency and intellectual property theft.

Read more

Would you like to see which other hedge funds own CLBT? Visit HoldingsChannel.com for the latest 13F filings and insider transactions for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).

Receive daily news and reviews for Cellebrite DI – Enter your email address below to receive a daily digest of the latest news and analyst ratings for Cellebrite DI and related companies with MarketBeat.com’s FREE daily email newsletter.